| 000 | 01807 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517192720.0 | ||
| 264 | 0 | _c20181105 | |
| 008 | 201811s 0 0 eng d | ||
| 022 | _a1873-2496 | ||
| 024 | 7 |
_a10.1016/j.urolonc.2017.11.021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchlütermann, David | |
| 245 | 0 | 0 |
_aTargeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. _h[electronic resource] |
| 260 |
_bUrologic oncology _c04 2018 |
||
| 300 |
_a160.e1-160.e13 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aAutophagy _xdrug effects |
| 650 | 0 | 4 |
_aCarcinoma, Transitional Cell _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 |
_aClass III Phosphatidylinositol 3-Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aUp-Regulation |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xdrug therapy |
| 700 | 1 | _aSkowron, Margaretha A | |
| 700 | 1 | _aBerleth, Niklas | |
| 700 | 1 | _aBöhler, Philip | |
| 700 | 1 | _aDeitersen, Jana | |
| 700 | 1 | _aStuhldreier, Fabian | |
| 700 | 1 | _aWallot-Hieke, Nora | |
| 700 | 1 | _aWu, Wenxian | |
| 700 | 1 | _aPeter, Christoph | |
| 700 | 1 | _aHoffmann, Michèle J | |
| 700 | 1 | _aNiegisch, Günter | |
| 700 | 1 | _aStork, Björn | |
| 773 | 0 |
_tUrologic oncology _gvol. 36 _gno. 4 _gp. 160.e1-160.e13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urolonc.2017.11.021 _zAvailable from publisher's website |
| 999 |
_c27923434 _d27923434 |
||